DK3190177T3 - Bioaktive nyreceller - Google Patents

Bioaktive nyreceller Download PDF

Info

Publication number
DK3190177T3
DK3190177T3 DK16196757.5T DK16196757T DK3190177T3 DK 3190177 T3 DK3190177 T3 DK 3190177T3 DK 16196757 T DK16196757 T DK 16196757T DK 3190177 T3 DK3190177 T3 DK 3190177T3
Authority
DK
Denmark
Prior art keywords
kidney cells
bioactive kidney
bioactive
cells
kidney
Prior art date
Application number
DK16196757.5T
Other languages
English (en)
Inventor
Roger M Ilagan
Russell W Keller
Sharon C Presnell
Sumana Choudhury
Andrew T Bruce
Christopher W Genheimer
Bryan R Cox
Kelly I Guthrie
Joydeep Basu
Shay M Wallace
Eric S Werdin
Oluwatoyin A Knight
Namrata D Sangha
John W Ludlow
Craig R Halberstadt
Richard Payne
Neil F Robins Jr
Darrell Mccoy
Deepak Jain
Manuel J Jayo
Elias A Rivera
Thomas Spencer
Benjamin Watts
Original Assignee
Prokidney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prokidney filed Critical Prokidney
Application granted granted Critical
Publication of DK3190177T3 publication Critical patent/DK3190177T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00Methods for the dissociation of cells, e.g. specific use of enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK16196757.5T 2010-05-12 2011-05-12 Bioaktive nyreceller DK3190177T3 (da)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US33403210P 2010-05-12 2010-05-12
US35389510P 2010-06-11 2010-06-11
US37207710P 2010-08-09 2010-08-09
US37188810P 2010-08-09 2010-08-09
US37658610P 2010-08-24 2010-08-24
US38876510P 2010-10-01 2010-10-01
US41293310P 2010-11-12 2010-11-12
US41338210P 2010-11-12 2010-11-12
US201161441423P 2011-02-10 2011-02-10
US201161473111P 2011-04-07 2011-04-07
EP11722663.9A EP2569418B1 (en) 2010-05-12 2011-05-12 Bioactive renal cells

Publications (1)

Publication Number Publication Date
DK3190177T3 true DK3190177T3 (da) 2022-01-31

Family

ID=44121234

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16196757.5T DK3190177T3 (da) 2010-05-12 2011-05-12 Bioaktive nyreceller

Country Status (14)

Country Link
US (4) US10077442B2 (da)
EP (3) EP4083191A1 (da)
JP (6) JP5974215B2 (da)
KR (5) KR102223564B1 (da)
CN (2) CN103154236B (da)
AU (5) AU2011252915B2 (da)
CA (1) CA2798900C (da)
DK (1) DK3190177T3 (da)
ES (1) ES2906750T3 (da)
HU (1) HUE058155T2 (da)
NZ (1) NZ603482A (da)
PL (1) PL3190177T3 (da)
TW (6) TWI629990B (da)
WO (1) WO2011143499A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
WO2011084791A2 (en) 2009-12-21 2011-07-14 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
CN103154236B (zh) 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
CN107823706B (zh) 2010-11-10 2022-02-01 因瑞金公司 用于器官增强的注射制剂
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
SI2912165T1 (sl) * 2012-10-24 2019-11-29 Inregen Populacije ledvičnih celic in njihova uporaba
JP6490669B2 (ja) * 2013-05-08 2019-03-27 インリージェン 単離腎細胞を含有するオルガノイド及びその使用
WO2015080838A1 (en) * 2013-11-27 2015-06-04 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis
US10941446B2 (en) 2014-03-12 2021-03-09 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
CN113444783B (zh) 2014-06-26 2024-04-09 西奈山伊坎医学院 通过分析预示性基因集诊断亚临床和临床的急性排异的方法
ES2897004T3 (es) 2014-06-26 2022-02-28 Icahn School Med Mount Sinai Métodos para diagnosticar el riesgo de fibrosis y rechazo de aloinjerto renal
CN107641614B (zh) * 2014-06-30 2020-11-20 中国人民解放军军事医学科学院野战输血研究所 微囊泡在诱导干细胞巨核分化中的用途
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN109477144B (zh) 2015-09-29 2022-12-09 国家儿童医院研究所 用于检测肝脏纤维化和对疗法的响应性的方法
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
EP3452100B1 (en) 2016-05-06 2020-12-16 Unicyte EV AG Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
KR101725025B1 (ko) * 2016-11-25 2017-04-10 서울대학교산학협력단 무형성골질환 진단용 miRNA 마커
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
CN107236799B (zh) * 2017-06-15 2020-06-09 昆明医科大学第六附属医院 一种肾纤维化miRNA标记物
CA3067558A1 (en) 2017-06-16 2018-12-20 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
MX2019014578A (es) * 2017-06-21 2020-12-01 Timothy A Bertram Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
CN111601890B (zh) * 2017-12-14 2024-04-19 联合细胞Ev股份公司 用于治疗肾癌的包含miRNA的药物载体
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
CA3095198A1 (en) 2018-04-16 2019-10-24 Icahn School Of Medicine At Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
TWI698640B (zh) * 2018-04-23 2020-07-11 長庚醫療財團法人高雄長庚紀念醫院 用於檢測狼瘡性腎炎或評估狼瘡性腎炎風險的方法及其應用
US12447179B2 (en) * 2018-08-31 2025-10-21 Prokidney Compositions comprising cell-delivered vesicles and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020092321A1 (en) * 2018-10-29 2020-05-07 Avery Therapeutics, Inc. Compositions and methods for cryopreservation and reconstitution of engineered tissues
CN111733234A (zh) * 2019-03-25 2020-10-02 深圳大学 一种食管癌分子标志物及其应用
KR20220042117A (ko) * 2019-08-09 2022-04-04 우베 고산 가부시키가이샤 엑소좀의 생성 방법
WO2021033605A1 (ja) * 2019-08-16 2021-02-25 公立大学法人名古屋市立大学 大腸癌診断用マーカー、大腸癌の診断を補助する方法、大腸癌の診断のためにデータを収集する方法、大腸癌の診断用キット、大腸癌治療薬、大腸癌の治療方法、大腸癌の診断方法
CN110734972B (zh) * 2019-11-28 2023-06-16 河北仁博科技有限公司 miR-181c-3p作为肾纤维化标志物的应用
CN115210361B (zh) * 2020-03-04 2024-12-10 淋巴奥格尼克斯有限公司 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物
EP4163364A4 (en) * 2020-06-08 2024-07-31 National University Corporation Tokyo Medical and Dental University CELL CULTURE PROCESS
CN112263587B (zh) * 2020-10-23 2022-08-30 河北仁博科技有限公司 miR-3065-5p在制备预防和/或治疗肾纤维化的药物中的应用
CN112760376B (zh) * 2020-12-30 2021-12-07 陈晓熠 miRNA-3918在非小细胞肺癌检测中的应用
WO2023107698A1 (en) * 2021-12-09 2023-06-15 Encellin, Inc. Methods and devices for pre-vascularization of implantation sites and/or cell encapsulation devices
CN115976211A (zh) * 2022-12-09 2023-04-18 深圳市科芮达健康科技有限公司 血液microRNA作为尿路上皮癌筛查或诊断标志物的用途、检测引物和试剂盒
CN116240161B (zh) * 2023-02-27 2024-05-10 四川大学华西医院 具有肾脏损伤修复作用的细胞外囊泡制备方法及应用
CN117853729B (zh) * 2024-01-10 2025-09-30 清华大学深圳国际研究生院 一种基于深度学习的多切面层次肾小球识别和匹配方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
CN1053698C (zh) 1989-01-19 2000-06-21 南京大学 细胞培养生产促红细胞生成素的方法
WO1990012604A1 (en) 1989-04-25 1990-11-01 Vacanti Joseph P Method for implanting large volumes of cells on polymeric matrices
WO1993007913A1 (en) 1991-10-24 1993-04-29 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
US5549674A (en) 1992-03-02 1996-08-27 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
JP2004155788A (ja) * 1998-09-24 2004-06-03 Tanabe Seiyaku Co Ltd 腎疾患治療薬およびそのスクリーニング方法
EP1180686B1 (en) 1999-05-27 2009-10-14 CMIC Co., Ltd. Remedies for kidney diseases and method for screening the same
KR100369788B1 (ko) 1999-09-03 2003-01-29 동아제약 주식회사 재조합 인간 에리트로포이에틴의 제조방법
WO2002061053A1 (en) 2001-01-31 2002-08-08 The General Hospital Corporation Renal stem cells and uses thereof
EP2292278B1 (en) 2001-11-16 2013-04-24 Children's Medical Center Corporation Augmentation of organ function
KR100964908B1 (ko) 2002-03-22 2010-06-23 깃세이 야쿠힌 고교 가부시키가이샤 신장질환의 예방 또는 치료제
JP2004309186A (ja) * 2003-04-02 2004-11-04 Tokai Univ 小胞体ストレスの改善剤およびその評価方法
ES2433493T3 (es) 2003-06-25 2013-12-11 Ottawa Hospital Research Institute Métodos y composiciones para modular el crecimiento de células pluripotenciales y la diferenciación
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
CA2663749A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
JP5269612B2 (ja) 2006-02-07 2013-08-21 スパイナルサイト, エルエルシー インビボバイオリアクターを使用する軟骨の修復のための方法および組成物
EP1987134A4 (en) 2006-02-10 2012-08-01 Tengion Inc EQUIPMENT FOR ORGANIC DESIGN AND AUGMENTATION
CA2676546A1 (en) 2006-04-24 2007-11-08 Stemcell Institute Inc. Method for preparing an organ for transplantation
WO2007127848A1 (en) * 2006-04-26 2007-11-08 University Of Louisville Research Foundation, Inc Isolation of membrane vesicles from biological fluids and methods of using same
WO2008045498A1 (en) 2006-10-12 2008-04-17 Ethicon, Inc. Kidney-derived cells and methods of use in tissue repair and regeneration
CA2667851A1 (en) 2006-11-16 2008-05-22 Genentech, Inc. Genetic variations associated with tumors
SG177225A1 (en) 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases
US7924332B2 (en) 2007-05-25 2011-04-12 The Trustees Of The University Of Pennsylvania Current/voltage mode image sensor with switchless active pixels
US9580688B2 (en) 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
EP2162529B1 (en) 2007-06-08 2019-03-27 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
DE102007033074A1 (de) * 2007-07-13 2009-01-15 Pac Tech-Packaging Technologies Gmbh Verfahren und Vorrichtung zur Entfernung von Lotmaterialdepots von einem Substrat
CN101854941B (zh) 2007-10-29 2013-03-27 弗雷森纽斯医疗护理德国有限责任公司 衍生自干细胞的微泡(MVs)用于制备用于受损或损伤组织或器官的内皮/上皮再生的药物的用途、以及相关体外和体内方法
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
BRPI0906867A2 (pt) * 2008-01-09 2019-09-24 Intrexon Corp inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo
KR101810799B1 (ko) 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
WO2010014643A1 (en) * 2008-07-28 2010-02-04 Virginia Tech Intellectual Properties, Inc. Irak-1 as regulator of diseases and disorders
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
KR101735125B1 (ko) * 2008-11-12 2017-05-15 리젠메드 (케이만) 엘티디. 분리된 신장 세포 및 이의 용도
WO2010057013A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
JP5565607B2 (ja) 2009-07-15 2014-08-06 国立大学法人 東京大学 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
EP2333047A1 (en) 2009-12-09 2011-06-15 Fresenius Medical Care Deutschland GmbH Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease
EP2363136A1 (en) 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
CN103154236B (zh) 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
WO2011156763A1 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
CN107823706B (zh) 2010-11-10 2022-02-01 因瑞金公司 用于器官增强的注射制剂
JP6643993B2 (ja) 2013-12-16 2020-02-12 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 膵島様細胞構造体及びそれを調製する方法
EP3443112B1 (en) 2016-04-12 2020-08-05 Unicyte EV AG Isolation of extracellular vesicles (evs) from biological fluid samples
EP3452100B1 (en) 2016-05-06 2020-12-16 Unicyte EV AG Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia

Also Published As

Publication number Publication date
KR20220112863A (ko) 2022-08-11
AU2011252915A1 (en) 2012-11-29
EP3190177B8 (en) 2022-07-27
JP2022153631A (ja) 2022-10-12
KR102428776B1 (ko) 2022-08-04
EP2569418A1 (en) 2013-03-20
JP7123426B2 (ja) 2022-08-23
HUE058155T2 (hu) 2022-07-28
KR102223564B1 (ko) 2021-03-05
JP2020201266A (ja) 2020-12-17
JP6744368B2 (ja) 2020-08-19
NZ809978A (en) 2025-07-25
AU2023202707A1 (en) 2023-05-18
KR102539589B1 (ko) 2023-06-01
CA2798900C (en) 2021-10-12
CN106214700B (zh) 2021-09-07
TWI762890B (zh) 2022-05-01
EP3190177A1 (en) 2017-07-12
TWI840787B (zh) 2024-05-01
JP2013528375A (ja) 2013-07-11
JP2024056860A (ja) 2024-04-23
US10077442B2 (en) 2018-09-18
TW201700106A (zh) 2017-01-01
CN103154236B (zh) 2016-08-31
CN103154236A (zh) 2013-06-12
JP7442852B2 (ja) 2024-03-05
EP4083191A1 (en) 2022-11-02
JP2018203746A (ja) 2018-12-27
TW201211255A (en) 2012-03-16
KR20210024686A (ko) 2021-03-05
US20210238600A1 (en) 2021-08-05
CA2798900A1 (en) 2011-11-17
TW201902494A (zh) 2019-01-16
AU2023202707B2 (en) 2026-04-09
CN106214700A (zh) 2016-12-14
HK1232143A1 (zh) 2018-01-05
US11066666B2 (en) 2021-07-20
EP3190177B1 (en) 2022-01-12
NZ796266A (en) 2024-04-26
JP5974215B2 (ja) 2016-08-24
PL3190177T3 (pl) 2022-06-06
KR101834830B1 (ko) 2018-04-19
AU2020203727A1 (en) 2020-06-25
AU2016216646B2 (en) 2017-11-09
US20160244751A1 (en) 2016-08-25
AU2011252915B2 (en) 2016-05-19
US12157887B2 (en) 2024-12-03
TWI690320B (zh) 2020-04-11
KR101975212B1 (ko) 2019-05-07
KR20180027604A (ko) 2018-03-14
JP6385976B2 (ja) 2018-09-05
KR20190047141A (ko) 2019-05-07
US20180282726A1 (en) 2018-10-04
TWI898523B (zh) 2025-09-21
JP2016208963A (ja) 2016-12-15
TW202027762A (zh) 2020-08-01
TWI542690B (zh) 2016-07-21
WO2011143499A1 (en) 2011-11-17
NZ603482A (en) 2014-11-28
AU2018200761A1 (en) 2018-02-22
ES2906750T3 (es) 2022-04-20
TW202228737A (zh) 2022-08-01
TWI629990B (zh) 2018-07-21
AU2020203727B2 (en) 2023-02-02
KR20130064753A (ko) 2013-06-18
AU2016216646A1 (en) 2016-09-01
US20240409941A1 (en) 2024-12-12
TW202532092A (zh) 2025-08-16
EP2569418B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
DK3190177T3 (da) Bioaktive nyreceller
DK3225404T3 (da) Fluidpatron
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
EP2543510A4 (en) LAMINATE
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2568873A4 (en) VACUUM RETRACTOR
EP2529782A4 (en) INTRODUCER SLEEVE ASSEMBLY
EP2433335A4 (en) Connector
DE112011104226A5 (de) Käfigmutter
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
EP2535065A4 (en) DIALYSIS MACHINE
EP2613409A4 (en) Connector
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102010038420A8 (de) Reinigungungsvorrichtung
DK2448659T3 (da) Rotorskive
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2441726A4 (en) LIFT
EP2571003A4 (en) RISK CALCULATION APPARATUS
EP2653308A4 (en) LAMINATE
DE112011102711A5 (de) Hydrostataktor